Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815371 | 1.00 | CNR2 (0.50) | CNR2GAAALDH1A1MAPTLMNA | |
| SCHEMBL478443 | 0.86 | CNR2 (0.59) | CNR2 | |
| SCHEMBL283367 | 0.79 | CNR2 (0.60) | CNR2 | |
| SCHEMBL2676458 | 0.77 | CNR2 (0.49) | CNR2GAAALDH1A1KDM4E | |
| SCHEMBL2676457 | 0.77 | CNR2 (0.49) | CNR2GAAALDH1A1KDM4E | |
| SCHEMBL283342 | 0.77 | CNR2 (0.51) | CNR2NPC1 | |
| SCHEMBL2814455 | 0.77 | CNR2 (0.51) | CNR2NPC1 | |
| SCHEMBL2815038 | 0.76 | CNR2 (0.66) | CNR2 | |
| SCHEMBL2815032 | 0.76 | CNR2 (0.66) | CNR2 | |
| SCHEMBL2814878 | 0.76 | CNR2 (0.50) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193713-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2851366-A1 | Compounds as cannabinoid receptor ligands | Abbvie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8492371-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885GAA 3257/4885ALDH1A1 926/4885 |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885GAA 2686/4885ALDH1A1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.